Ryan & Maniskas, LLP Announces Investigation Of Medicis Pharmaceutical Corp.

Ryan & Maniskas, LLP ( www.rmclasslaw.com/cases/mrx) is investigating potential claims against the board of directors of Medicis Pharmaceutical Corp. (“Medicis” or the “Company”) (NYSE: MRX) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Medicis to Valeant Pharmaceuticals International Inc. in a transaction valued at approximately $2.6 billion.

Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by the Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Medicis. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/mdx.

Under the terms of the transaction, Medicis shareholders will receive $44 in cash for each share of Medicis they own.

If you own shares of Medicis and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/mdx. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

Copyright Business Wire 2010

If you liked this article you might like

Apple Turns 40 With Little Fanfare as March to Dow 20K Resumes: ICYMI

Medicis Stock Hits New 52-Week High (MRX)

Medicis Pharmaceuticals Corporation (MRX): Today's Featured Drugs Laggard

Medicis Stock To Go Ex-dividend Tomorrow (MRX)

Cramer's 'Mad Money' Recap: The Worse It Gets, the Better